Lanthanum carbonate

×

Overview

What is Lanthanum carbonate?

LANTHANUM CARBONATE contains lanthanum carbonate with molecular formula La(CO) xHO (on average x=4-5 moles of water) and molecular weight 457.8 (anhydrous mass). Lanthanum carbonate is described as white to almost white powder. Lanthanum carbonate is practically insoluble in water and is insoluble in organic solvents; it dissolves in dilute mineral acids with effervescence.

Each LANTHANUM CARBONATE white to off-white, chewable tablet contains lanthanum carbonate hydrate equivalent to 500, 750, or 1000 mg of elemental lanthanum and the following inactive ingredients: colloidal silicon dioxide NF, dextrates (hydrated) NF, magnesium stearate NF.

What does Lanthanum carbonate look like?

What are the available doses of Lanthanum carbonate?

LANTHANUM CARBONATE Chewable Tablets: 500 mg, 750 mg, and 1000 mg.

What should I talk to my health care provider before I take Lanthanum carbonate?

How should I use Lanthanum carbonate?

LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Management of elevated serum phosphorus levels in end stage renal disease patients usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis and reduction of intestinal phosphate absorption with phosphate binders.

Divide the total daily dose of LANTHANUM CARBONATE and take with or immediately after meals. The recommended initial total daily dose of LANTHANUM CARBONATE is 1500 mg. Titrate the dose every 2-3 weeks until an acceptable serum phosphate level is reached. Monitor serum phosphate levels as needed during dose titration and on a regular basis thereafter.

In clinical studies of ESRD patients, LANTHANUM CARBONATE doses up to 4500 mg were evaluated. Most patients required a total daily dose between 1500 mg and 3000 mg to reduce plasma phosphate levels to less than 6.0 mg/dL. Doses were generally titrated in increments of 750 mg/day.

Chew or crush LANTHANUM CARBONATE completely before swallowing. Do not swallow intact LANTHANUM CARBONATE Chewable Tablets.

Consider using the oral powder formulation in patients with poor dentition or who have difficulty chewing tablets.

What interacts with Lanthanum carbonate?

Sorry No Records found

What are the warnings of Lanthanum carbonate?

Sorry No Records found

What are the precautions of Lanthanum carbonate?

Sorry No Records found

What are the side effects of Lanthanum carbonate?

Sorry No records found

What should I look out for while using Lanthanum carbonate?

Contraindicated in bowel obstruction, including ileus and fecal impaction.

What might happen if I take too much Lanthanum carbonate?

The symptoms associated with overdose are adverse reactions such as headache, nausea and vomiting. In clinical trials in healthy adults, GI symptoms were reported with daily doses up to 6000 mg/day of lanthanum carbonate administered with food. Given the topical activity of lanthanum in the gut, and the excretion in feces of the majority of the dose, supportive therapy is recommended for overdosage. Lanthanum carbonate was not acutely toxic in animals by the oral route. No deaths and no adverse effects occurred in mice, rats or dogs after single oral doses of 2000 mg/kg (1.7, 3.4, and 11.3 times the MRHD, respectively, on a mg/m basis).

How should I store and handle Lanthanum carbonate?

Store at 20 to 25C (68 to 77F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.LANTHANUM CARBONATE is supplied as a chewable tablet in three dosage strengths for oral administration: 500 mg tablets, 750 mg tablets, and 1000 mg tablets. Each chewable tablet is white to off-white round, flat with a bevelled edge, and debossed on one side with 'S405' and the dosage strength corresponding to the content of elemental lanthanum.500 mg Patient Pack (2 bottles of 45 tablets, NDC 66993-422-47, per each patient pack) NDC 66993-422-85.750 mg Patient Pack (6 bottles of 15 tablets, NDC 66993-423-53, per each patient pack) NDC 66993-423-85. 1000 mg Patient Pack (9 bottles of 10 tablets, NDC 66993-424-75, per each patient pack) NDC 66993-424-85.LANTHANUM CARBONATE is supplied as a chewable tablet in three dosage strengths for oral administration: 500 mg tablets, 750 mg tablets, and 1000 mg tablets. Each chewable tablet is white to off-white round, flat with a bevelled edge, and debossed on one side with 'S405' and the dosage strength corresponding to the content of elemental lanthanum.500 mg Patient Pack (2 bottles of 45 tablets, NDC 66993-422-47, per each patient pack) NDC 66993-422-85.750 mg Patient Pack (6 bottles of 15 tablets, NDC 66993-423-53, per each patient pack) NDC 66993-423-85. 1000 mg Patient Pack (9 bottles of 10 tablets, NDC 66993-424-75, per each patient pack) NDC 66993-424-85.LANTHANUM CARBONATE is supplied as a chewable tablet in three dosage strengths for oral administration: 500 mg tablets, 750 mg tablets, and 1000 mg tablets. Each chewable tablet is white to off-white round, flat with a bevelled edge, and debossed on one side with 'S405' and the dosage strength corresponding to the content of elemental lanthanum.500 mg Patient Pack (2 bottles of 45 tablets, NDC 66993-422-47, per each patient pack) NDC 66993-422-85.750 mg Patient Pack (6 bottles of 15 tablets, NDC 66993-423-53, per each patient pack) NDC 66993-423-85. 1000 mg Patient Pack (9 bottles of 10 tablets, NDC 66993-424-75, per each patient pack) NDC 66993-424-85.LANTHANUM CARBONATE is supplied as a chewable tablet in three dosage strengths for oral administration: 500 mg tablets, 750 mg tablets, and 1000 mg tablets. Each chewable tablet is white to off-white round, flat with a bevelled edge, and debossed on one side with 'S405' and the dosage strength corresponding to the content of elemental lanthanum.500 mg Patient Pack (2 bottles of 45 tablets, NDC 66993-422-47, per each patient pack) NDC 66993-422-85.750 mg Patient Pack (6 bottles of 15 tablets, NDC 66993-423-53, per each patient pack) NDC 66993-423-85. 1000 mg Patient Pack (9 bottles of 10 tablets, NDC 66993-424-75, per each patient pack) NDC 66993-424-85.

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

LANTHANUM CARBONATE is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the gastrointestinal (GI) tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.

Non-Clinical Toxicology

Contraindicated in bowel obstruction, including ileus and fecal impaction.

Drug interactions:

Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation and fecal impaction have been reported in patients taking lanthanum, some requiring surgery or hospitalization.

Risk factors for gastrointestinal obstruction and gastrointestinal perforation identified from post-marketing reports in patients taking LANTHANUM CARBONATE Chewable Tablets include altered gastrointestinal anatomy (e.g., diverticular disease, peritonitis, history of gastrointestinal surgery, gastrointestinal cancer, gastrointestinal ulceration), hypomotility disorders (e.g., constipation, ileus, subileus, diabetic gastroparesis) and concomitant medications (e.g., calcium channel blockers). Some cases were reported in patients with no history of gastrointestinal disease.

Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease or bowel obstruction were not included in LANTHANUM CARBONATE clinical studies

Advise patients who are prescribed LANTHANUM CARBONATE Chewable Tablets to chew the tablet completely to reduce the risk of serious adverse gastrointestinal events such as those described above.

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Overall, the safety profile of LANTHANUM CARBONATE has been studied in over 5200 subjects in completed clinical trials. The most common adverse reactions for LANTHANUM CARBONATE were gastrointestinal events, such as nausea, vomiting, and abdominal pain and they generally abated over time with continued dosing.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: